机构:[1]Shenzhen Geno-Immune Medical Institute, 518000 Shenzhen, China[2]PKUHKUST Shenzhen-Hong Kong Institution, 518057 Shenzhen, China[3]National Research Center for Hematology, Moscow 125167, Russia[4]The Third Affiliated Hospital of Kunming Medical University, Cancer Hospital of Yunnan, 650118 Kunming, Yunnan, China[5]University of Electronic Science and Technology of China, 611731 Chengdu, Sichuan, China[6]Peking University, Shenzhen Institute, Shenzhen Key Lab Human Tissue Regenerate & Repair, 518057 Shenzhen, China
This study was supported by research funds from Science
and Technology Planning Technical Research Project of Shenzhen
(JCYJ20170413154349187, JCYJ20170817172416991, JCYJ20170817172541842,
and KQTD20140630143254906).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|1 区医学
小类|1 区肿瘤学1 区血液学
最新[2023]版:
大类|1 区医学
小类|1 区血液学1 区肿瘤学
第一作者:
第一作者机构:[1]Shenzhen Geno-Immune Medical Institute, 518000 Shenzhen, China[2]PKUHKUST Shenzhen-Hong Kong Institution, 518057 Shenzhen, China
共同第一作者:
通讯作者:
通讯机构:[1]Shenzhen Geno-Immune Medical Institute, 518000 Shenzhen, China[5]University of Electronic Science and Technology of China, 611731 Chengdu, Sichuan, China
推荐引用方式(GB/T 7714):
Jiao Cheng,Zvonkov Eugene,Lai Xun,et al.4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas.[J].Blood cancer journal.2021,11(3):59.doi:10.1038/s41408-021-00455-x.
APA:
Jiao Cheng,Zvonkov Eugene,Lai Xun,Zhang Rui,Liu Yuchen...&Chang Lung-Ji.(2021).4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas..Blood cancer journal,11,(3)
MLA:
Jiao Cheng,et al."4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas.".Blood cancer journal 11..3(2021):59